Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD).
With no novel treatments approved in over 10 years for the disease, Dupixent could be on the verge of breaking that long drought. What could this mean for Sanofi's future revenue? Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.
COPD is a potentially fatal respiratory condition that harms the lungs and causes progressive lung function deterioration. Common physical symptoms of the condition include a persistent cough and shortness of breath, which can interfere with daily activities when severe enough. Unsurprisingly, the physical challenges of COPD can also result in depression, anxiety, and insomnia.
Source Fool.com
